[ad_1]
NEW YORK, February 1, 2019 / PRNewswire / – A Retrospective Analysis – Published in the Newspaper Research and treatment of bad cancer, by Judith Malmgren, PhD and co-authors – studied 8292 women with stage I-III invasive bad cancer, of whom 964 (11.6%) were subsequently diagnosed with recurrent metastatic bad cancer (cancer recurrent metastatic bad). The authors found a significant decrease in rMBC rate over time, but no increase in survival. Survival after diagnosis of CMRb decreased over time from 23% between 1990 and 1998 to 21% between 1999 and 2004 and 13% between 2005 and 2011.
Judith MalmgrenPhD, The lead author of the study said: "While this is encouraging and highlights the success of the current modalities of invasive bad cancer treatment, the lack of improvement in survival after a distant recidivism is worrying ".
An earlier study by the MBC Alliance, in partnership with the National Cancer Institute, estimated that about 155,000 people in United States live with MBC. Next, these authors studied two types of CDM, de novo CDM and distant recurrence after a diagnosis of invasive bad cancer, and found better survival after a de novo CDM diagnosis. The results of the current study and the previous study show that patients with chronic skin cancer suffer less well over time than compared to patients with de novo bad cancer. Dr. Malmgren, The lead author of both studies noted that the results of this study "reinforce the difference in survival after the diagnosis of stage IV bad cancer de novo compared to a distant recurrence after a bad cancer diagnosis." invasive ".
The current study also aimed to explore receptor subtypes in detail. The incidence of HER2 + and hormone receptor (HR) + rMBC both decreased, but the incidence of triple negative rMBC (HER2- and HR-) did not decrease resulting in a relative increase in the triple negative rMBC as a whole. Dr. Malmgren commented that "this underscores the lack of successful treatment of initial triple negative bad cancer and creates a real challenge of clinical treatment". Author of the study Henry Kaplan, MD, stated that "although triple-negative bad cancer is still a very big problem, several new treatments are being evaluated in both BRCA mutant and wild-type BRCA patients, including new chemotherapy, immunotherapies and medications the effects of genetic mutations that predispose a patient to a triple negative disease. "
New and better treatments in recent decades, including Herceptin® (trastuzumab) for HER2 + bad cancer and hormone therapy for HR + bad cancer probably resulted in decreased recurrence of these subtypes. Therefore, the current population of CBRM is more likely to be triple negative and / or to be more pretreated, regardless of the subtype. These features make treatment of CBMR more difficult and may have contributed to the degradation of observed survival over time.
"The current study led by Dr. Malmgren builds on the body of research conducted by the MBC Alliance to answer key questions about the epidemiology of metastatic bad cancer," he said. note Shirley Mertz, President of the MBC Alliance. "In our 2014 MBC Landscape Analysis, we identified a lack of information on the epidemiology of the MBC.The Alliance has developed key questions on the epidemiology of MBC related to the incidence, prevalence and outcomes, and their evolution over time.The latest study is the third in a series of research publications inspired by the MBC Alliance to answer these questions. "
As stated in the new document, current goals for improving the survival of patients with chronic bronchial cancer include targeted treatment and better treatments for early-stage triple-negative patients, screening and sensitization. improved treatment regimens for chronic bronchial cancer and universal care in line with guidelines. Patients of the Swedish Cancer Institute receive care in accordance with NCCN guidelines. Dr. Malmgren noted that very few HR + or HER2 + recurrences occur in these patients. She said, "This level of care should be available to all women diagnosed with bad cancer."
Authors and affiliations of the study:
Judith MalmgrenPhD, badistant professor of epidemiology, University of Washington School of Public Health and President of HealthStat Consulting, Inc., Seattle, WA
Marc Hurlbert, PhD, Alliance for Metastatic Breast Cancer
Mary Atwood, Swedish Cancer Institute, Seattle, WA
Henry Kaplan, MD, Head of the Breast Cancer Service in Medical Oncology at the Swedish Cancer Institute and Clinical Professor of Medicine, University of Washington
The study was funded by the Kaplan Cancer Research Fund, the Metastatic Breast Cancer Alliance and the National Cancer Institute's Cancer Surveillance System (CSS) Surveillance Epidemiology and End-Outcomes (SEER) program.
About the Swedish Cancer Institute
The Swedish Cancer Institute (SCI) opened in 1932 as the first cancer treatment center west of the Mississippi. For 75 years, it has been the largest and most comprehensive cancer treatment program in the Pacific Northwest. A true multidisciplinary program, SCI offers a wide range of advanced cancer treatment options in chemotherapy, radiotherapy and surgery, supported by extensive diagnostic capabilities, patient education and support group services. The clinical research component of SCI includes collaborative therapeutic trials, cancer screening and prevention trials and investigator-initiated, industry-sponsored and group-initiated trials. Breast cancer screening and diagnosis are available in Swedish bad treatment centers and mobile mammography units. For more information, visit www.swedish.org.
About the Kaplan Cancer Research Fund
The Swedish Kaplan Cancer Research Fund was established in 1984 as a series of grants Henry Kaplan had benefited from similar research related to experimental drug trials and had continued with similar funding as well as significant philanthropic support. Research has focused on the appropriate use of mammography, the results of bad cancer treatments, the effects of chemotherapy drugs on the development of hematological malignancies, the pharmacology of chemotherapy drugs, the genomics of cancer and clinical trials of drugs. For more information, visit http://www.swedishfoundation.org/kaplan.
About the MBC Alliance
The Metastatic Breast Cancer Alliance (MBC Alliance) is a coalition of 32 non-profit organizations and 11 pharmaceutical / biotech companies, as well as 17 patient advocates, many of whom live with MBC. The mission of the MBC Alliance is to improve the lives and outcomes of people living with the MBC and their families by educating and educating the public about the disease and advancing political and strategic coordination of research funding. , specifically focused on metastasis, which opportunity to prolong life, improve the quality of life and ultimately heal. To accomplish this mission, the objectives of the MBC Alliance are to advance CBM research, increase access to CBM information and support services, and increase understanding of how MBC is different from bad cancer at an early stage. For more information, visit https://www.mbcalliance.org.
Media contact:
Laurie Campbell
646-239-7872
[email protected]
SOURCE Metastatic Alliance for Breast Cancer
Related Links
https://www.mbcalliance.org
Source link
